Role of EMT in Metastasis and Therapy Resistance

Smith, Bethany N.; Bhowmick, Neil A.

doi:10.3390/jcm5020017

Cited by 401 publications

(323 citation statements)

References 123 publications

(172 reference statements)

Supporting

Mentioning

311

Contrasting

Unclassified

Order By: Relevance

“…According to progression of cancer, cancer cells seems to acquire the ability of invasion and metastasis by EMT (24). Several studies already suggested that Wnt signaling pathway closely related to EMT (25,26), and EMT related factors would be prognostic factors of ESCC (27,28). These studies support the hypothesis that the canonical Wnt signaling pathway activates the progression and metastasis of ESCC through the EMT; whether Wnt3a expression might also be correlated with the progression and metastasis of ESCC should be investigated.…”

Section: Discussionsupporting

confidence: 68%

Wnt3a expression is associated with poor prognosis of esophageal squamous cell carcinoma

et al. 2017

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 68%

Wnt3a expression is associated with poor prognosis of esophageal squamous cell carcinoma

et al. 2017

View full text Add to dashboard Cite

“…49,50 Many evidences demonstrated that EMT contributes to cancer progression, metastasis, tumor microenvironment crosstalk, and drug resistance. 51,52 EMT-induced cancer cells have been changed a lot at the molecular level and display increased expression of mesenchymal genes (fibronectin, N-cadherin, and vimentin) and decreased expression of epithelial genes (E-cadherin and ZO-1). 52,53 In many cases, gain of N-cadherin and loss of E-cadherin are unique features of EMT.…”

Section: Esophageal Squamous Cell Carcinomamentioning

confidence: 99%

SPRY4-IT1: A novel oncogenic long non-coding RNA in human cancers

Chen

et al. 2017

Tumour Biol.

View full text Add to dashboard Cite

Long non-coding RNAs are classified as a kind of RNA, which are longer than 200 nucleotides in length and cannot be translated into proteins. Multiple studies have demonstrated that long non-coding RNAs are involved in various cellular processes, including proliferation, differentiation, cell death, and metastasis. Among numerous long non-coding RNAs, we focus on Sprouty4-Intron 1 (SPRY4-IT1), a well-known long non-coding RNA that is overexpressed in various kinds of tumor tissues and cell lines. Accumulating evidences show that SPRY4-IT1 was dysregulated in various cancers, including melanoma, breast cancer, esophageal squamous cell carcinoma, non-small cell lung cancer, gastric cancer, colon cancer, and hepatocellular carcinoma, and amplification of SPRY4-IT1 was associated with different clinicopathological features of cancer patients. Importantly, SPRY4-IT1 exerts important roles in tumor progression and metastasis. However, detailed molecular mechanisms of SPRY4-IT1 in cancer progression and metastasis were poorly understood. In this review, we have focused on the characteristics of SPRY4-IT1 and illustrated the biological function and mechanism of SPRY4-IT1 in cancer development.

show abstract

“…It is now well known that EMT is a physiological cellular mechanism that tumor cells borrow during the metastatic process. In this way, in many human cancers, the HGF/cMET pathway participates in malignant progression and cell scattering, invasion, and protection from apoptosis, and in metastasis formation [Fujita and Sugano, 1997;Samamé Pérez-Vargas et al 2013;Smith and Bhowmick, 2016].…”

Section: Molecular Heterogeneity Of Colorectal Cancermentioning

confidence: 99%

The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care

Rosa

Rega

Costabile

et al. 2016

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Colorectal cancer has been ranked the third and second most prevalent of all cancers in men and women, respectively, and it represents the fourth most common cause of cancer deaths. In 2012, there were 1.4 million estimated cases of colorectal cancer worldwide, and 700,000 estimated deaths, which implies significant impact on public health, especially in economically-developed countries. In recent years, there has been an increase in the number of tumors, although this has been accompanied by decreased mortality, due to more appropriate and available information, earlier diagnosis, and improvements in treatment. Colorectal cancers are characterized by great genotypic and phenotypic heterogeneity, including tumor microenvironment and interactions between healthy and cancer cells. All of these traits confer a unique peculiarity to each tumor, which can thus be considered as an individual disease. Well conducted molecular and clinical characterization of each colorectal cancer is essential with a view to the implementation of precision oncology, and thus personalized care. This last aims at standardization of therapeutic plans chosen according to the genetic background of each specific neoplasm, to increase overall survival and reduce treatment side effects. Thus, prognostic and predictive molecular biomarkers assume a critical role in the characterization of colorectal cancer and in the determination of the most appropriate therapy

show abstract

Role of EMT in Metastasis and Therapy Resistance

Cited by 401 publications

References 123 publications

Wnt3a expression is associated with poor prognosis of esophageal squamous cell carcinoma

Wnt3a expression is associated with poor prognosis of esophageal squamous cell carcinoma

SPRY4-IT1: A novel oncogenic long non-coding RNA in human cancers

The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care

Contact Info

Product

Resources

About